Evidence overview
CoQ10
Coenzyme Q10 (CoQ10) is among the most-studied mitochondrial cofactors, with a research base anchored most strongly in statin-associated muscle symptoms, migraine prevention, and cardiovascular risk markers. The field's reference documents are condition-specific meta-analyses rather than umbrella reviews or position stands. The evidence is substantial but mixed by indication.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Lipid-soluble compound essential to mitochondrial electron-transport-chain function, where it shuttles electrons between complexes I/II...
Study coverage
Study coverage by goal
PubMed counts for CoQ10 grouped by the goal each study targets.
Evidence overview is temporarily unavailable for CoQ10.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
CoQ10 is studied in two principal supplement forms: ubiquinone (the oxidized form, the original and still-dominant trial form) and ubiquinol (the reduced form, more bioavailable on a per-milligram basis but more expensive). Direct head-to-head comparisons are limited; the bulk of the trial literature uses ubiquinone. Endogenous CoQ10 synthesis declines with age and is meaningfully reduced by statins, which shapes the populations the literature most often targets.
The outcome dimensions covered most heavily are statin-associated muscle symptoms (the indication CoQ10 is most often clinically prescribed for), migraine prophylaxis, heart-failure-related markers, blood pressure, lipid profiles, fertility (oocyte quality, male sperm parameters), and exercise recovery. The literature is dense in the cardiovascular and statin-myopathy areas; thinner in fertility despite repeated meta-analyses on the topic. CoQ10 is also commonly co-formulated with selenium in cardiovascular trials, which complicates attribution.
Demographically, older adults dominate the cardiovascular and statin-myopathy literature; reproductive-age women feature heavily in the fertility literature. The migraine literature is more demographically diverse but smaller. Baseline CoQ10 status is rarely measured (the assay is expensive and not routinely available), so trials cannot easily distinguish supplementation effects from correction of subclinical deficiency.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
CoQ10 is generally well-tolerated in clinical trials, including at doses up to 1,200 mg/day in some studies. The most-reported adverse events are mild gastrointestinal discomfort (nausea, loose stools), insomnia at higher doses, and headache. No established tolerable upper limit exists. Drug interactions to watch include warfarin (CoQ10 is structurally similar to vitamin K and may modestly reduce anticoagulant effect; INR monitoring is recommended for warfarin users), antihypertensives (additive blood-pressure-lowering observed in some trials), and chemotherapy agents (theoretical antioxidant interference debated in the oncology literature). People on warfarin or with active cancer should consult a clinician before starting.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
The reference meta-analysis on CoQ10 for statin-induced muscle symptoms - the indication CoQ10 is most often clinically prescribed for. Published in a high-impact cardiovascular journal and consistently cited as the field's anchor when CoQ10 is discussed in cardiology and lipidology contexts.
View on PubMedPooled-evidence document on CoQ10's effects on lipid profiles, published in a major endocrinology journal. Establishes the reference point for CoQ10's role in cardiovascular and metabolic contexts beyond statin myopathy.
View on PubMedThe principal pooled-evidence document on CoQ10 for migraine prophylaxis, the second-most-cited clinical use for the supplement. Establishes the methodological reference point for newer migraine-prevention guidelines that consider non-pharmacological adjuncts.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the CoQ10 literature at a general level. It does not address which form (ubiquinone vs. ubiquinol) is right for your goal, what dose your specific indication calls for, whether your baseline status warrants supplementation, or how CoQ10 interacts with the medications you take (especially warfarin, antihypertensives, or statins themselves). The personalized report incorporates those details. Crucially, the CoQ10 literature is condition-specific rather than supplement-overall - the field does not have a single umbrella review on the supplement, so whether CoQ10 is right for you depends heavily on which indication you're considering it for.
Personalized to you
Get a personalized CoQ10 report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on CoQ10 materially updates. No account required.